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Abstract 
Background: Paracrine disruption of growth factors in women with polycystic ovarian syndrome (PCOS) results in 
production of low quality oocyte, especially following ovulation induction. The aim of this study was to investigate 
the effects of metformin (MET), N-acetylcysteine (NAC) and their combination on the hormonal levels and expres-
sion profile of GDF-9, BMP-15 and c-kit, as hallmarks of oocyte quality, in PCOS patients.
Materials and Methods: This prospective randomized, double-blind, placebo controlled trial aims to study the effects 
of MET, NAC and their combination (MET+NAC) on expression of GDF-9, BMP-15 and c-kit mRNA in oocytes 
[10 at the germinal vesicle (GV) stage, 10 at the MI stage, and 10 at the MII stage from per group] derived following 
ovulation induction in PCOS. Treatment was carried out for six weeks, starting on the third day of previous cycle until 
oocyte aspiration. The expression of GDF9, BMP15 and c-kit were determined by quantitative real time polymerase 
chain reaction (RT-qPCR) and western blot analysis. Data were analyzed with one-way ANOVA.
Results: The follicular fluid (FF) level of c-kit protein significantly decreased in the NAC group compared to the other 
groups. Significant correlations were observed between the FF soluble c-kit protein with FF volume, androstenedione 
and estradiol. The GDF-9 expression in unfertilized mature oocytes were significantly higher in the NAC group com-
pared to the other groups (P<0.001). Similar difference was not observed between the MET, NAC+MET and control 
groups. The c-kit expression in unfertilized mature oocytes were significantly lower in the NAC group compared to 
the other groups (P<0.001). Similar difference was not observed between the MET, NAC+MET and control groups 
(Registration number: IRCT201204159476N1). 
Conclusion: : We concluded that NAC can improve the quality of oocytes in PCOS.
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Introduction 
Anovulation associated with polycystic ovary syn-
drome (PCOS), as a common metabolic disorder, is the 
major cause of female infertility (1, 2). The principal 
feature of PCOS is the large number of follicles arrest-
ing at early growth stage. The cytoplasmic and nuclear 
maturity of oocytes is reduced following ovarian stim-
ulation and may account for embryo quality in these 
couples (3). Exclusive oocyte secreted factors (OSFs), 
such as growth differentiation factor-9 (GDF-9) and 
bone morphogenetic factor-15 (BMP-15), belonging to 
transforming growth factor-β superfamily, are essential 
for oocyte competence (3-5). The receptor tyrosine ki-
nase c-kit is another OSFs which plays important role 
in oogenesis and folliculogenesis (6). Recent evidence 
suggest possible involvement of c-kit and its receptor, 
kit ligand (KL) in PCOS pathology (7). Indeed, it has 
been shown that the aberrant or low expression of these 
exclusive oocyte secreting factors (BMP-15 and GDF-
9), lead to over expression of c-kit and its receptor (8-
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10). Therefore, drugs which can modulate the regula-
tion of these intra-ovarian factors may play a role in the 
clinical management of PCOS. 
To improve the quality of oocyte, various protocol 
for have been designed, tested and verified for ovula-
tion induction along with insulin-sensitizing drugs in 
PCOS patients. But, the risks of poor response, ovarian 
hyperstimulation, production of low quality oocytes, 
reduced fertilization rates and poor embryo quality re-
mains among concern to be dealt within PCOS women 
undergoing in vitro fertilization (IVF) or intracytoplas-
mic sperm injection (ICSI) (11). Metformin, an insu-
lin-lowering agent, has been extensively used for treat-
ment of anovulation and infertility in PCOS patients. 
However, the efficacy of MET treatment is still disput-
ed (12). In this regard, background studies indicate that 
MET does not improve the overall outcomes of assisted 
reproductive procedure in term of the aforementioned 
parameters (13, 14). 
On the contrary, administration of N-acetylcysteine 
(NAC) has been shown to improve not only the num-
ber and also the quality of oocytes in these patients. 
This phenomenon has been mainly related to the strong 
antioxidant effect of NAC, which has been shown to 
reduce follicle atresia and improve the quality of oo-
cyte (15). In vitro, NAC plays a key role in cell survival 
through the production of trophic factor and follicular 
preservation (16, 17). In line with these reports, Sac-
chinelli et al. (18) showed that co-administration of 
inositol and NAC improve ovarian function of PCOS 
patients. Therefore, considering the fact that oocyte 
secretory factors are hallmarks of oocyte quality, this 
study aims to evaluate the effects of NAC, MET and 
their co-administration on the expression of GDF-9, 
BMP-15 and c-kit in PCOS individuals undergoing 
ovarian stimulation in ICSI cycle.
Materials and Methods
Antibodies directed against c-kit and β-actin was 
obtained from Cell Signaling Technology (Beverly, 
MA, USA). BMP-15 antibody was obtained from Ab-
cam Technology (Cambridge, MA, USA) and GDF-9 
antibody from Santa Cruz Biotechnology (CA, USA). 
Other reagents used in this study were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Cell culture me-
dia and sera were obtained from Gibco BRL (Carlsbad, 
CA, USA).
Study design
This study was performed in continuation of our pro-
spective randomized, double-blind, placebo controlled 
trial, in the IVF Unit of Infertility Research Center of 
the Academic Center for Education, Culture and Re-
search (ACECR), Qom/Iran. 80 infertile PCOS wom-
en at the age of 25-35 years, in the interval between 
July 2012 and February 2013, who planned to undergo 
ICSI were included in this study (19). Individuals were 
diagnosed as PCOS according to the Rotterdam con-
sensus workshop (20). Based on this consensus, each 
individual needed to have two out of three criteria: i. 
Biochemical or clinical hyperandrogenism, ii. Chronic 
oligo or anovulation and iii. Polycystic ovaries at ultra-
sound examination. Ethical consideration and further 
information on this clinical trial are provided in previ-
ous studies (19). This study was approved by the Ethics 
Committee (EC/91/1041) of Royan Institute, Tehran, 
Iran. The patients provided an informed consent and 
committed to avoid any changes in their normal physi-
cal activity, diet or starting a new medical regimen 
throughout the study.
Treatment design and ovulation induction
The female partner of ICSI candidates were exam-
ined and randomly divided into 4 groups (n=20): i. 
Placebo (PLA) receiving oral rehydration solution 
(ORS, Poursina, Iran), ii. MET receiving MET (Glu-
cophage, Merck, West Drayton, UK, 500 mg), iii. 
NAC receiving NAC (Holzkrichen, Germany, batch 
no. 6N5483, 600 mg), and iv. MET+NAC group re-
ceiving the combination of MET and NAC at the 
aforementioned doses. Treatment was carried out 
three times daily for a period of six weeks. The dose 
and duration of NAC treatment was chosen according 
to recent studies (21-23). 
Gonadotropin-releasing hormone (GnRH) agonist 
protocol (18) was used to induce ovulation. The female 
partner of ICSI candidates randomized to four groups 
received PLA, MET, NAC or MET+NAC from the third 
day of last menstrual period (LMP) of previous cycle 
until the day of oocyte aspiration. Oral contraceptive 
pills (OCPs) were also included in the regimen for 21 
days starting simultaneously with placebo, MET, NAC 
or MET+NAC on the day 3 of menstrual cycle prior 
to the treatment cycle. For ovarian down-regulation, 
daily injections of Bucerelin acetate (1 mg, Suprefact, 
Aventis, Germany) were administered from the day 19 
of the preceding, menstrual cycle until day 2 of the next 
cycle. On the second day on the next cycle if the en-
dometrial thickness was less than  4 mm, the dose of 
Burcerelin acetate was reduced to 0.5 mg.  
Ovulation induction was induced from the day two of 
the cycle with average daily injections of 2 ampoules 
of recombinant follicle stimulating hormone (rFSH, 
Gonal-f, Merck Serono S.A., Geneva, Switzerland). 
Vaginal ultrasound (Honda Electronics HS 4000-Ja-
pan) was also used to monitor the cycles. 10,000 IU 
human chorionic gonadotropin (hCG, Pregnyl, Orga-
non, Netherlands) was administered to induce ovula-
tion. 36 hours after the administration of hCG, when at 
least three follicles had reached the diameters of 16-18 
mm, transvaginal oocyte aspiration was performed un-
der ultrasound guidance and general anesthesia. This 
protocol of induction ovulation was used for all the in-
dividuals in the 4 group. During the treatment the par-
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ticipants were asked to report any probable side effects 
such as abdominal discomfort, diarrhea and nausea. 
Due to these side effects, 20 couples (5 per group) were 
excluded from the study (Fig.1).
Preparation of oocytes, follicular fluid and blood samples
Based on our pervious study, oocytes and follicular 
fluid (FF) from multiple follicles, from each subject 
were pooled as explained (18). Following oocyte re-
trieval, their cumulus cells were removed by exposure 
to 20 IU/ml hyaluronidase (ART-4007A, SAGE BioP-
harma, USA) in HEPES-based medium for 30 seconds 
followed by mechanical pipetting in HEPES-buffered 
HTF containing 5 mg/ml human serum albumin (ART-
3001, SAGE BioPharma, USA). 
The nuclear status of each oocyte was determined 
under the stereo microscope (Olympus Co., Japan) and 
classified into three categories: i. Unfertilized mature 
oocyte [metaphase II (MII)] following ICSI, ii. Ger-
minal vesicle (GV) stage, iii. Without first polar body 
called metaphase I (MI). For gene expression analysis, 
in each experimental group, 10 GV, 10 MI, and 10 MII 
oocytes were separately pooled and washed in phos-
phate-buffered saline (PBS) and transferred into RNase-
free microcentrifuge tubes. 50 μl of RNAlater, RNA Sta-
bilization Reagent (Qiagen, USA) were added to each 
tube and all samples were stored in a -80°C freezer until 
analysis. Only MII oocytes were used for ICSI.
The FF, from the first aspirated with no visible blood 
contamination was collect and immediately centri-
fuged at 3000 rpm for 10 minutes, and the superna-
tants were stored at -70°C for further analysis. Fasting 
blood sample were also collected from each participant 
once prior to the start of treatment (day 2 of pervious 
cycle) and once on the day of ovum pick up of ICSI 
cycle. The samples were immediately centrifuged for 
10 minutes at 3000 rpm (Hettich, EBA20, UK) and the 
resulting serum were stored at -70°C for evaluation. 
The levels of luteinizing hormone (LH, mIU/ml), FSH 
(mIU/ml), total testosterone (TT, ng/ml), Progesterone 
(ng/ml), estradiol (E2, pg/ml) and androstenedione (ng/
ml) in the FF and serum were measured in all samples 
using the ELISA enzyme immunoassay (Demeditec Diag-
nostics GmbH, Germany) according to the manufacturer’s 
protocol. The FF soluble protein level of c-Kit (pg/ml) 
was measured with the ELISA Kit (Abnova Corporation, 
Taiwan) by sandwich enzyme immunoassay technique, 
according to the manufacturer’s protocol.
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Fig.1: Flowchart of participants in this study.
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Gene expression analysis 
Total RNA from the oocytes of each group were iso-
lated using the EZ-10 total RNA mini-prep Kit (Bio 
Basic Inc., Canada), according to the manufactur-
er's protocol. All samples were stored at -80ºC till 
analysis. Complementary DNA (cDNA) was synthe-
sized, using random hexamers [using the RevertAid 
First Strand cDNA synthesis Kit (Thermo scientific, 
USA)]. To determine the relative expression of target 
genes, quantitative real time polymerase chain reac-
tion (RT-qPCR) was carried out using SYBR-Green/
ROX qPCR master mix assay (Thermo scientific, 
USA) by gene-specific primers (Table 1). Relative 
gene expression was calculated as the abundance ra-
tio of each target gene relative to β-actin. The ABI 
step one plus (ABI, USA) instrument was used for 
real time PCR experiments and the ΔΔCt method for 
data calculation. 
Table 1: Identity and sequence details of polymerase chain reaction (PCR) 
primers used to analyses mRNA expression in oocytes
Sequence primer (5´-3´)Gene
F: CCAATAGAAGTCACCTC
R: GCGATCCAGGTTAAATAGCA
GDF-9
F: CAGTCCTCTATTGCCCTTCT
R: AATGGTGCGGTTCTCTCTA 
BMP-15
F: ACGAATGAGAATAAGCAGAATGAA
R: GAGAGGACAGCGGACCAG 
c-Kit
F: GGACTTCGAGCAAGAGATGG
R: AGCACTGTGTTGGCGTACAG
β-actin
Total proteins from each pool of oocytes were extract-
ed using RIPA lysis and extraction buffer Kit (Cat No: 
89900, Thermo Scientific, USA), according to the manu-
facturer’s instruction. Concentration of proteins was de-
termined according to Bradford’s method using bovine 
serum albumin (BSA) as a reference standard (Bradford, 
1976). Total proteins were electrophoresed in 12.5% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) gel, transferred to polyvinylidene fluoride 
membranes, and probed with specific antibodies. Mem-
branes were developed using enhanced chemilumines-
cence reagents (Amersham Bioscience, USA) and the 
intensity of immunoreactive polypeptides was analyzed 
subsequent to visualization of the bands developed on a 
photographic film. Protein bands on photographic film 
were quantified by densitometry scanning after back-
ground subtraction. Integrated densities of bands were 
measured by Image J software.
Statistics
The normality of continuous variables was confirmed 
using the Kolmogrov-Smirnov test and data were report-
ed as means ± SEM. Data analysis were performed using 
one-way ANOVA and Tukey’s test for post-hoc. Means 
were considered significantly different at P<0.05. Pear-
son’s correlation test defined the relation between vari-
ables. All data were analyzed with the statistical software 
SPSS (version16.0 for windows, Chicago, IL, USA).
Results
Patients characteristics including age, body mass index 
(BMI), the level of LH, FSH, E2 and TT were not signifi-
cantly different among the groups PCOS prior to treatment.
Follicular fluid analysis
FF volume and FF level of androstenedione, E2 and 
progesterone were similar in all groups (P>0.05, Table 2), 
but the level of soluble c-kit protein in the FF significantly 
decreased in the NAC group compared to other groups 
(P<0.01). Our results also showed a significant correla-
tion between the soluble c-kit protein in the FF of all the 
population with the FF volume (r=0.508, P=0.02), andros-
tenedione (r=0.682, P=0.01), and E2 (r=0.638, P=0.01) 
(Fig.2). 
Evaluation of oocyte and embryo quality
The number of immature oocytes (MI+GV) and abnor-
mal mature oocytes significantly decreased in the NAC 
group (P<0.01) compared to the other groups. Similar 
reduction was also observed in MET and MET+NAC 
groups but the reduction was not significant compared 
to the placebo group (P>0.05). The fertilization rate of 
metaphase II oocytes were similar in all groups (P>0.05). 
The number of good embryo (grade I) on day 3 showed a 
significant increase in the NAC group (P<0.02) compared 
to placebo group. This improvement was also observed in 
the MET and MET+NAC groups when compared to the 
placebo (P>0.05), but remained insignificant (Fig.3). The 
percentage of top grad embryos was not different between 
the three NAC with MET and MET+NAC groups.
Table 2: Comparison of the biochemical parameters of follicular fluid in PCOS patients
PlANAC+METMETNACParameter
4.9 ± 1.1a4.96 ± 1.1a5.7 ± 1.1a5.4 ± 1.13aFollicular fluid Volume (ml)
436 ± 40.16a470.2 ± 48.4a496.6 ± 44.8a466.6 ± 34.8aEstradiol (pg/ml)
3255.3 ± 414.8a3501.2 ± 326.9a3916.9 ± 359.5a3983.7 ± 353.9aProgesterone (ng/ml)
548.3 ± 42.36a487.6 ± 42.9a435.2 ± 46.7a426.2 ± 30.3aAndrostenedione (ng/ml)
455.2 ± 28.75a429.8 ± 28.7a380.8 ± 30.3a317.8 ± 27.5bSoluble c-Kit (pg/ml)
Data are shown as mean ± SEM. Analysis was performed by ANOVA and Tukey’s test for multiple comparisons.  
Means without a common letter are significantly different (P<0.05). PCOS; Polycystic ovarian syndrome, MET; Metformin, and NAC; N-acetylcysteine, and PLA; Placebo.
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Expression profile of GDF-9, BMP-15 and c-Kit in 
oocytes 
The level of BMP-15 protein in the mature unfertilized 
oocytes and GV oocytes did not differ significantly among 
the groups (P>0.05, Figs.4, 5A, D, E). The expression lev-
el of GDF-9 in the GV oocytes significantly increased in 
all groups compared to the placebo (P<0.001) (Fig.4B, D, 
F), while for unfertilized mature oocytes, GDF-9 mRNA 
and protein levels only significantly increased in the NAC 
group (P<0.001, Fig.5B, D, F). The expression of c-kit in 
the GV oocytes significantly decreased in the NAC and 
MET groups compared to the placebo group (P<0.001), 
but not in NAC+MET group (Fig.4C, D, G). The c-kit 
expression in the unfertilized mature oocytes significantly 
decreased in the NAC group compared to the MET and 
other treatment groups (P<0.001), but no significant dif-
ference was found in the MET and NAC+MET groups 
when compared to the placebo group (P>0.05, Fig.5C, D, 
G). It is important to note that the results for MI oocytes 
were similar to GV oocyte; therefore, in this article only 
the results of GV were presented. This observation is in 
accordance with pervious literature (24).
Fig.2: Correlation between parameters of follicular fluid (FF) in all the population. A. Soluble c-Kit with volume of FF, B. Estradiol (E2), and C. Androsten-
edione. R2; Determination of coefficient.
Fig.3: Distribution of oocytes retrieved, quality of oocytes and embryos in polycystic ovary syndrome patients undergoing treatment of N-acetylcysteine 
(NAC), metformin (MET), NAC+MET and Placebo (control). 
Data are the mean ± SEM. Statistical analyses were performed by ANOVA followed by Tukey’s test for multiple comparisons. Means without a common 
letter are significantly different (P<0.05). 
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Fig.4: Effects of NAC and MET on BMP-15, GDF-9 and c-kit mRNA and protein expression in immature oocytes (IMO, GV oocytes) of PCOS patients. Results 
of reverse transcriptase real-time polymerase chain reaction (PCR) for mRNAs of A. BMP-15, B. GDF-9, C. c-kit in GV oocytes, D. Immunoblots of BMP-15, 
GDF-9 and c-kit from oocyte cell lysates. Densities of E. BMP-15, F. GDF-9, and G. c-kit protein bands in the experimental groups are shown. Means without 
a common letter are significantly different (P<0.05). 
NAC; N-acetylcysteine, MET; Metformin, GV; Germinal vesicle, and PCOS; Polycystic ovarian syndrome.
b b
b
0
0.5
1
1.5
2
2.5
3
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
BMP15-IMO
Beta-actin
50 kDa
45 kDa
D
GDF9-IMO 51 kDa
c-kit-IMO 145 kDa
BMP15-IMO
Beta-actin
50 kDa
45 kDa
D
GDF9-IMO 51 kDa
c-kit-IMO 145 kDa
0
0.05
0.1
0.15
0.2
0.25
0.3
Placebo Met NAC Met+NAC
B
M
P-
15
/β
-a
ct
in
 ra
tio
 
(A
rb
itr
ar
y 
un
it)
E
0
0.05
0.1
0.15
0.2
0.25
0.3
Placebo Met NAC Met+NAC
B
M
P-
15
/β
-a
ct
in
 ra
tio
 
(A
rb
itr
ar
y 
un
it)
E
b
0
0.2
0.4
0.6
0.8
1
Placebo Met NAC Met+NAC
F
G
D
F-
9/
β
-a
ct
in
 r
at
io
 (A
rb
itr
ar
y 
un
it)
b
0
0.2
0.4
0.6
0.8
1
Placebo Met NAC Met+NAC
F
G
D
F-
9/
β
-a
ct
in
 r
at
io
 (A
rb
itr
ar
y 
un
it)
0
0.2
0.4
0.6
0.8
1
1.2
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 
BM
P-
15
 m
R
N
A
 le
ve
l
A
a a a a
0
0.2
0.4
0.6
0.8
1
1.2
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 
BM
P-
15
 m
R
N
A
 le
ve
l
A
a a a a
0
0.2
0.4
0.6
0.8
1
Placebo Met NAC Met+NAC
c-
Ki
t/
β
-a
ct
in
 ra
tio
 
(A
rb
itr
ar
y 
un
it)
G
.
.
.
.
lace et et
c-
Ki
t/
β
-a
ct
in
 ra
tio
 
(A
rb
itr
ar
y 
un
it)
b b
0
0.2
0.4
0.6
0.8
1
1.2
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 
c-
ki
tm
R
N
A
 le
ve
l
a a
C
b b
0
0.2
0.4
0.6
0.8
1
1.2
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 
c-
ki
tm
R
N
A
 le
ve
l
a a
C
b b
b
0.5
1
1.5
2
2.5
3
Placebo MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
b b
b
0.5
1
1.5
2
2.5
3
MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
b b
b
0
0.5
1
1.5
2
2.5
3
Placeb ET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
0
.
.
.
l c bo
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
b b
b
0
0.5
1
1.5
2
2.5
3
Placebo MET ET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
b b
b
0
0.5
1
1.5
2
2.5
3
Placebo ET ET
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
b b
b
0
0.5
1
1.5
2
2.5
Placebo ET ET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
b b
b
0
0.5
1
1.5
2
2.5
3
Placebo MET NAC ET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
b b
b
0
0.5
1
1.5
2
2.5
3
Pla MET NAC MET+NAC
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
.
.
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
b b
b
0
0.5
1
1.5
2
2.5
3
Placebo ET ET
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
a
B
+
R
el
at
iv
e 
qu
an
tif
ic
at
io
n 
of
 G
D
F9
m
R
N
A
 le
ve
l
Int J Fertil Steril, Vol 11, No 4, Jan-Mar 2018              276
Fig.5: Effects of NAC and MET on BMP-15, GDF-9 and c-kit mRNA and protein expression in unfertilized mature oocytes (UMO, MII oocytes) of PCOS 
patients. Results of reverse transcriptase real-time polymerase chain reaction (PCR) for mRNAs of A. BMP-15, B. GDF-9, C. c-kit in MII oocytes, D. Immu-
noblots of BMP-15, GDF-9 and c-kit from oocyte cell lysates. Densities of E. BMP-15, F. GDF-9, and G. c-kit protein bands in the experimental groups are 
shown. Means without a common letter are significantly different (P<0.05). 
NAC; N-acetylcysteine, MET; Metformin, and PCOS; Polycystic ovarian syndrome.
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Discussion
A typical characteristic of PCOS patient commonly ob-
served during induction stimulation for ART cycles is in-
creased number of low quality oocytes which is mainly 
related to state of endocrine disorder in these individuals 
(25). Considering the indispensable role of OSFs in oocyte 
development and maturation, many researches have shown 
impaired expression of OSFs particularly GDF-9, BMP-
15 and c-kit, may account for low quality oocyte in PCOS 
undergoing ovarian stimulation (26). This may explain, at 
least a part of the folliculogenesis disorders found in these 
patients (27-29). Background literature in this filed is very 
discrepant. Some authors have reported reduce expression 
of GDF-9 with no significant alteration in the expression 
of BMP-15 (8), while others have shown no alteration in 
expression of these two factors both at RNA and protein 
level (9) in oocyte of PCOS individuals. The exact reason 
of such discrepancy is not well understood.
In continue to our previous study, we demonstrated that 
unlike MTE and NAC+MET groups, the administration 
of NAC compared to placebo group, improves the matura-
tion and quality of oocytes and also embryo development 
in PCOS patients undergoing ICSI (18). Therefore, in this 
we aimed to evaluate whether NAC could alter BMP-15, 
GDF-9 and c-kit levels, as the main OSFs in the oocytes 
of PCOS patients in comparison to MET and MET+NAC. 
Compelling evidence suggest that GDF-9 and BMP-15 
members of the TGFβ superfamily are exclusively expressed 
in the oocyte and their expression increases as follicle devel-
opment progresses (30). During postnatal ovarian develop-
ment, c-kit mRNA and protein are localized in the oocytes 
(6), and in this regard Brankin et al. (31) has shown a re-
lation between KL/c-kit interaction with antrum formation, 
steroidogenesis and oocyte quality. Furthermore, genetic and 
descriptive studies have implicated the involvement of c-kit 
receptor and its ligand, KL, in oocyte growth (32).
Low GDF-9 levels is associated with abnormally in-
creased KL level in PCOS, which could lead to abnormal 
ovarian features such as enlarged oocytes and increased 
follicle numbers (7, 32). In PCOS patients, the GDF-9 
mRNA level within  the oocytes is lower than in oocyte 
derived from normal individuals (8), and it is believed 
that there is a negative association between GDF-9 ex-
pression and KL/c-kit expression. Tuck (7) believes that 
excess androgens may act to further reduce the inhibitory 
effect of GDF-9, thus resulting in an abnormal increase in 
the  KL/c-kit protein level in PCOS individual. Consider-
ing the inverse relationship between c-kit and GDF-9 in 
PCOS (7, 8, 32), therefore, improving the expression of 
GDF-9 is expected to cause a reduction in c-kit levels.
Our results displayed a significant increase in the ex-
pression of GDF-9 in the unfertilized mature oocytes of 
PCOS patients after administration of NAC compared 
to MET, indicating that NAC, as an anti-oxidant/anti-
apoptotic agent, could enhance the expression of GDF-9 
through inhibiting the activity of NF-kB and AP-1 tran-
scription factors, therefore affecting the activity of MAP-
kinase signaling and related genes expression (33), which 
may be able to alleviate PCOS follicular disorders and 
prevent follicular developmental detention and atresia. 
Our study, in agreement with aforementioned studies, also 
showed a significant decrease in the expression of c-kit in 
the oocytes of PCOS patients and also the soluble c-kit pro-
tein in the FF following administration of NAC compared to 
control. In addition, evidence has indicated the relationship 
between KL/c-kit system with MAPK pathway and/or PI3K/
Akt pathway, which are both necessary for follicle develop-
ment (34). It is likely that NAC decreases the expression 
of c-kit through interference in MAPK pathway, all of this 
could be the underlying reason in the role of NAC in pre-
venting follicular developmental detention and atresia and 
alleviation of follicular disorders in PCOS patients.
Although the FF content may be an invaluable hallmark 
for PCOS diagnosis, but the NAC ability to modulate 
these intra-ovarian factors of the oocyte may have inter-
esting pharmacological perspectives for clinical manage-
ment of PCOS patients. According to literature (7, 8, 32), 
there is an inverse relationship between c-kit and GDF-9. 
Therefore, improves expression of GDF-9 by NAC treat-
ment, is expected to follow by a reduction in c-Kit and 
indeed MET appears to mask this effect of NAC, how this 
masking effect is performed, remains to be elucidated.
In this regard it has been shown that with increased fol-
licular size and E2 production, the amount of soluble c-kit 
protein in human FF also increase (35), which is consist-
ent with the correlation observed in this study between 
soluble c-kit with the FF volume, E2, and androstenedi-
one concentrations. 
It has been demonstrated that the excess secretion of 
anti-mullerian hormone (AMH) in  the FF of PCOS pa-
tients may directly inhibit the production of OSFs such 
as GDF-9 and BMP-15, which can explain the low lev-
els of OSFs in PCOS oocytes (36). Our findings showed 
a reduction in the AMH level in the FF of NAC treated 
group (18). Although this reduction was not statistically 
significant but may be considered as an underlying reason 
for the increased levels of GDF-9 in the NAC treated pa-
tients. Moreover, in agreement with other findings (8, 9), 
our study revealed no significant difference in the level of 
BMP-15 mRNA among the studies groups.
Conclusion
Considering the fact that NAC improves oocyte matura-
tion and embryo quality, and decreases the rate of immature 
oocytes in women with PCOS while being a safe and well-
tolerated agent, we suggest the administration of NAC as 
an alternative to other insulin-sensitizing agents like MET. 
Therefore, the present study argues that NAC possibly im-
proves the oocyte quality of PCOS patients compared to 
MET through modulating the c-kit and GDF-9 expression, 
indicating that NAC supplement may be a therapeutic alter-
native to the insulin-sensitizing agents in PCOS management. 
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